CompBrief BY VELARION

Companies Passage BIO, Inc.

Passage BIO CEO salary & total pay, FY2025: $1.5M

Passage BIO (PASG) CEO salary, fiscal 2025: William Chou was paid a salary of $660,985 and $1,486,763 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Passage BIO, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

William Chou's complete compensation dossier

A PDF and a CSV sent to your email: William Chou's pay in every fiscal year Passage BIO, Inc. reported it, line by line, with William Chou's equity grants and Passage BIO, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$1,486,763CEO William Chou · source
Say-on-pay support97.56%Latest vote · source
CEO vs. named peers62nd pct.Of 17 peer CEOs

CEO pay, last three years

  • $1,448,545FY2023
  • $1,636,770FY2024
  • $1,486,763FY2025

CEO total pay was $1,486,763 in fiscal 2025, down from $1,636,770 in fiscal 2024.

FY2025: salary $660,985 · stock awards $234,040 · option awards $239,266

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Passage BIO, Inc. in fiscal 2025?
As disclosed, William Chou (President, Chief Executive Officer and Director) was the highest-paid executive at Passage BIO, Inc. in fiscal 2025, with total compensation of $1,486,763.
How does Passage BIO, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, William Chou's total compensation ranked at the 62nd percentile of Passage BIO, Inc.'s disclosed peer group.
How did shareholders vote on Passage BIO, Inc.'s executive compensation?
As disclosed, 97.56% of shareholders supported Passage BIO, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Passage BIO, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Passage BIO, Inc. reported total board compensation of $369,021 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
William Chou$660,985—$234,040$239,266$334,972—$17,500$1,486,763
President, Chief Executive Officer and Director
Kathleen Borthwick450,627—117,02085,440181,252—17,500851,839
Chief Financial Officer
Edgar Cale221,860—197,080156,8500—17,500593,290
General Counsel and Corporate Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
William Chou$1,486,763$1,636,770$1,448,545↓ −150,007
Kathleen Borthwick851,839861,698—↓ −9,859
Edgar Cale593,290881,920949,726↓ −288,630

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company seeks to design and implement a competitive executive compensation program that combines both cash and incentive elements based on annual performance objectives and long-term equity elements that will be flexible and complementary to meet our compensation objectives. The Compensation Committee regularly reviews all compensation components to ensure they are consistent with short-term and long-term goals.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantPearl Meyer
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Edgar CaleOption13,712—161.37—
Edgar CaleOption4,986—360—
Edgar CaleOption8,549—437—
Edgar CaleOption5,299—90.4—
Edgar CaleOption5,000—36—
Edgar CaleOption5,299—45.8—
Edgar CaleOption8,749—21.6—
Edgar CaleOption10,149—30—
Edgar CaleOption2,499—14—
Edgar CaleOption13,918—7.74—
Kathleen BorthwickOption1,89385621.6—
Kathleen BorthwickOption60439517.55—
Kathleen BorthwickOption4,9666,38430—
Kathleen BorthwickRSU—10,000—118,000
Kathleen BorthwickOption2,61011,3087.74—
Kathleen BorthwickOption2,799—135—
Kathleen BorthwickOption1,043—45.8—
William ChouOption8,6952,28026.4—
William ChouOption26,3446,93026.4—
William ChouOption20,9229,50721.6—
William ChouOption12,57916,17030—
William ChouRSU—20,000—236,000
William ChouOption7,30831,6687.74—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Maxine Gowen, Ph.DIndependent · Board Chair · Compensation · Nominating/Governance · Audit$83,500—$55,000—$0$138,500
Sandip KapadiaIndependent · Audit55,000—55,000—0110,000
Athena Countouriotis, M.DIndependent · Audit · Compensation (Chair)54,181—55,000—0109,181
Derrell Porter, M.DIndependent · Compensation · Nominating/Governance · Audit49,500—55,000—0104,500
Dolan Sondhi, Ph.DIndependent · Nominating/Governance44,000—55,000—099,000
Saqib IslamNot independent · Departed during FY35,340—55,000—090,340
Thomas KassbergIndependent · Audit47,500—39,176—086,676
William Chou, M.DEmployee director · Nominating/Governance—————0

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$55,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 12,000 / 8,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$369,021
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$369,021

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Passage BIO as a peer

Companies that benchmark against PASG

The list of companies that name PASG as a peer is temporarily unavailable — recheck shortly.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Aligos Therapeutics, Inc.2025Lawrence Blatt$651,718$0$3,014,995$371,479$4,057,234
2Jasper Therapeutics, Inc.2025Ronald Martell727,27201,766,82702,494,099
3ALX Oncology Holdings Inc.2025Jason Lettmann724,50001,447,488298,8562,470,844
4Century Therapeutics, Inc.2025Brent Pfeiffenberger640,6251,869,609222,681317,1092,381,022
5Precision BioSciences, Inc.2025Michael Amoroso650,8751,025,086002,189,467
6Passage BIO, Inc.2025William Chou660,985234,040239,266334,9721,486,763
7AN2 Therapeutics, Inc.2025Eric Easom603,750164,133275,539332,0631,382,985
8Kezar Life Sciences, Inc.2025Christopher Kirk618,0000588,82801,220,828
9Actinium Pharmaceuticals, Inc.2025Sandesh Seth762,3200001,187,320
10Lisata Therapeutics, Inc.2025David Mazzo711,729307,800104,08001,147,359
11NextCure, Inc.2025Michael Richman609,2580189,170122,000941,692
12Kala BIO, Inc.2025Mark Iwicki111,866166,413627,4670906,642
13PDS Biotechnology Corporation2025Frank Bedu-Addo615,3220193,5000828,307
14Celularity Inc.2025Robert Hariri600,000000650,651
—Lantern Pharma Inc.——————not in coverage universe
—BioAtla, Inc.——————not in coverage universe
—Xilio Therapeutics, Inc.——————not in coverage universe
—Immunic, Inc.——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Passage BIO, Inc.not disclosednot disclosednot disclosedPearl Meyer
Actinium Pharmaceuticals, Inc.not disclosednot disclosednot disclosedStreeterWyatt Analytics LLC
Aligos Therapeutics, Inc.not disclosedOption 100not disclosedRadford
ALX Oncology Holdings Inc.not disclosednot disclosednot disclosedCompensia
AN2 Therapeutics, Inc.not disclosednot disclosednot disclosedAon
BioAtla, Inc.not disclosednot disclosednot disclosednot disclosed
Celularity Inc.not disclosedOption 66.67 · RSU 33.33not disclosednot disclosed
Century Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Immunic, Inc.not disclosednot disclosednot disclosednot disclosed
Jasper Therapeutics, Inc.not disclosedOption 100not disclosednot disclosed
Kala BIO, Inc.not disclosednot disclosednot disclosedPearl Meyer & Partners, LLC
Kezar Life Sciences, Inc.not disclosedOption 100not disclosednot disclosed
Lantern Pharma Inc.not disclosednot disclosednot disclosednot disclosed
Lisata Therapeutics, Inc.not disclosednot disclosednot disclosedRadford/AON
NextCure, Inc.not disclosedOption 100not disclosedPearl Meyer & Partners, LLC
PDS Biotechnology Corporationnot disclosednot disclosednot disclosednot disclosed
Precision BioSciences, Inc.115%RSU 100not disclosedAon
Xilio Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-191,452,50536,3521,35697.56%Passed
20252025-05-28—————
2024——————
2022——————
20212021-05-27—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
2022——a
2024——b
20262026-05-1997.56%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Approved under the standard stated in the filing — “Advisory approval of this proposal requires the affirmative vote of the holders of a majority of the voting power of the shares present online at the virtual Annual Meeting or represented by proxy at the Annual Meeting and voting affirmatively or negatively (excluding abstentions and broker non-votes) on this proposal.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Sandip KapadiaDirector2026-05-19A10,539$0$0Derivative, Class A CommonForm 4 ↗
Athena CountouriotisDirector2026-05-19A10,53900Derivative, Class A CommonForm 4 ↗
Maxine GowenDirector2026-05-19A10,53900Derivative, Class A CommonForm 4 ↗
Thomas KassbergDirector2026-05-19A10,53900Derivative, Class A CommonForm 4 ↗
Derrell PorterDirector2026-05-19A10,53900Derivative, Class A CommonForm 4 ↗
Dolan SondhiDirector2026-05-19A10,53900Derivative, Class A CommonForm 4 ↗
Lynx1 Capital Management LPGreater-than-10% holder2026-06-25A50,0554206,101Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (37 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, William Chou. DEF 14A, filed 2026-04-07. Section “Executive Compensation”. As printed: 1,486,763. View filing ↗
  • Section 01, Kathleen Borthwick. DEF 14A, filed 2026-04-07. Section “Executive Compensation”. As printed: 851,839. View filing ↗
  • Section 01, Edgar Cale. DEF 14A, filed 2026-04-07. Section “Executive Compensation”. As printed: 593,290. View filing ↗
  • Section 08, Maxine Gowen, Ph.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 138,500. View filing ↗
  • Section 08, Sandip Kapadia. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 110,000. View filing ↗
  • Section 08, Athena Countouriotis, M.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 109,181. View filing ↗
  • Section 08, Derrell Porter, M.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 104,500. View filing ↗
  • Section 08, Dolan Sondhi, Ph.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 99,000. View filing ↗
  • Section 08, Saqib Islam. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 90,340. View filing ↗
  • Section 08, Thomas Kassberg. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 86,676. View filing ↗
  • Section 08, William Chou, M.D. DEF 14A, filed 2026-04-07. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Sandip Kapadia 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Athena Countouriotis 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Maxine Gowen 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Kassberg 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Derrell Porter 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dolan Sondhi 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lynx1 Capital Management LP 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-03-03. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-10-24. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-05-26. Item 5.07 · say-on-pay result. As reported: 97.56% (votes for as printed: 1,452,505). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 369,021 + equity 0 + all other 0 = 369,021, summed across the director compensation table rows.
  • Aligos Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Aligos Therapeutics, Inc.'s own proxy. As printed: 4,057,234. View filing ↗
  • Jasper Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-15. CEO total compensation as printed in Jasper Therapeutics, Inc.'s own proxy. As printed: 2,494,099. View filing ↗
  • ALX Oncology Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology Holdings Inc.'s own proxy. As printed: 2,470,844. View filing ↗
  • Century Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Century Therapeutics, Inc.'s own proxy. As printed: 2,381,022. View filing ↗
  • Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
  • Passage BIO, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Passage BIO, Inc.'s own proxy. As printed: 1,486,763. View filing ↗
  • AN2 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in AN2 Therapeutics, Inc.'s own proxy. As printed: 1,382,985. View filing ↗
  • Kezar Life Sciences, Inc., Section 10b CEO total. 10-K/A, filed 2026-04-30. CEO total compensation as printed in Kezar Life Sciences, Inc.'s own proxy. As printed: 1,220,828. View filing ↗
  • Actinium Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Actinium Pharmaceuticals, Inc.'s own proxy. As printed: 1,187,320. View filing ↗
  • Lisata Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-19. CEO total compensation as printed in Lisata Therapeutics, Inc.'s own proxy. As printed: 1,147,359. View filing ↗
  • NextCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in NextCure, Inc.'s own proxy. As printed: 941,692. View filing ↗
  • Kala BIO, Inc., Section 10b CEO total. DEF 14A, filed 2026-09-24. CEO total compensation as printed in Kala BIO, Inc.'s own proxy. As printed: 906,642. View filing ↗
  • PDS Biotechnology Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in PDS Biotechnology Corporation's own proxy. As printed: 828,307. View filing ↗
  • Celularity Inc., Section 10b CEO total. DEF 14A, filed 2026-11-10. CEO total compensation as printed in Celularity Inc.'s own proxy. As printed: 650,651. View filing ↗
Get the full report — $299